Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYE201 in BRVO, DME, and NVAMD
NCT06664502Phase 2Completed
- Sponsor
- EyeBio
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of tiespectus in branch retinal vein occlusion (BRVO), diabetic macular edema (DME) and neovascular age-related macular degeneration (NVAMD) (8 arms), sponsored by EyeBio. Primary endpoint: Adverse Events at 12 weeks. Started Nov 2024; status: completed.
02
Drugs
tiespectus
03
Conditions
branch retinal vein occlusion (BRVO)diabetic macular edema (DME)neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06664502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664502.